tirzepatide dysesthesia 28.7% Weight Loss in New Retatrutide Study – Dr Brad Stanfield Dysesthesia associated with GLP-1 agonist

Individuals with Cardiovascular Conditions: Elevated levels of GH and IGF-1 may affect blood pressure, water retention, and heart rate

In the global TRIUMPH-4 trial, adults with obesity and knee osteoarthritis treated with the highest dose of retatrutide lost an average of 28.7% of their body weight over 68 weeks roughly 32 kg per patient while also showing marked improvements in pain and physical function related to osteoarthritis

Know when to ask for help If constipation becomes persistent, painful, or severe, it is important to speak with your healthcare provider

2 In addition to metabolic and androgen improvements, GLP-1 RAs appear to influence menstrual cyclicity positively